{
  "company": "Qiagen N.V.",
  "ticker": "QGEN",
  "period": {
    "from": "2026-02-27",
    "to": "2026-03-29",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 24,
    "negative": 12,
    "neutral": 36
  },
  "synthesis": {
    "executive_summary": "**Executive Summary: Qiagen N.V. (QGEN) Sentiment Analysis**\n\nSentiment analysis for Qiagen N.V. (QGEN) from February 27 to March 29, 2026, indicates a predominantly neutral sentiment with a positive lean. Of 72 analyzed items, 50% were neutral, 33% positive, and 17% negative. Positive sentiment was driven by Qiagen's stable position in molecular diagnostics, significant advancements in infectious disease testing (specifically for tuberculosis and gastrointestinal panels), and strategic focus on high-growth areas. Conversely, negative sentiment stemmed primarily from the company's stock performance, notably reaching a new 52-week low, and specific technical discussions related to product application and a recent partnership.\n\nSignificant positive developments included new clinical data validating the efficacy of Qiagen's QuantiFERON-TB Gold Plus test, which demonstrated reduced TB progression risk and potential healthcare cost savings. Additionally, FDA clearance for QIAstat-Dx Gastrointestinal Panels further strengthened its market position in infectious disease diagnostics. Conversely, a prominent negative event was QGEN's stock hitting a new 52-week low of USD 39.26, reflecting a 13.83% year-over-year decline. Furthermore, a partnership with Gencurix to expand digital PCR cancer assays, while strategically aligned, was notably categorized with negative sentiment in some analyses. This was compounded by user-reported technical challenges concerning specific lab protocols utilizing Qiagen products.",
    "key_findings": [
      "✓ Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
      "✓ Qiagen’s TB And GI Testing Moves Draw Investor Valuation Interest",
      "✓ QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
      "✗ Sanger Sequencing Problem!!",
      "✗ Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays",
      "✗ Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays"
    ],
    "overall_sentiment": "positive"
  },
  "top_positive": [
    {
      "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.637
    },
    {
      "title": "Qiagen’s TB And GI Testing Moves Draw Investor Valuation Interest",
      "date": "2026-03-19",
      "source": "alpha_vantage",
      "score": 0.459
    },
    {
      "title": "QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
      "date": "2026-03-19",
      "source": "alpha_vantage",
      "score": 0.44
    },
    {
      "title": "QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
      "date": "2026-03-19",
      "source": "alpha_vantage",
      "score": 0.44
    },
    {
      "title": "QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
      "date": "2026-03-19",
      "source": "reddit",
      "score": 0.44
    },
    {
      "title": "Today's Analyst Upgrade: Deutsche Bank Recommends Buy for QGEN | QGEN Stock News",
      "date": "2026-03-13",
      "source": "alpha_vantage",
      "score": 0.426
    },
    {
      "title": "Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": 0.421
    },
    {
      "title": "Qiagen N.V. stock gains spotlight with new QuantiFERON-TB data amid genomics challenges",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": 0.402
    },
    {
      "title": "EverHint – EMA10 × EMA30 Crossover – Top 10 Buy and Top 10 Sell Signals for Mar 25, 2026",
      "date": "2026-03-26",
      "source": "reddit",
      "score": 0.382
    },
    {
      "title": "PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act]",
      "date": "2026-03-20",
      "source": "alpha_vantage",
      "score": 0.296
    }
  ],
  "top_negative": [
    {
      "title": "Sanger Sequencing Problem!!",
      "date": "2026-03-06",
      "source": "reddit",
      "score": -0.508
    },
    {
      "title": "Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays",
      "date": "2026-03-19",
      "source": "alpha_vantage",
      "score": -0.477
    },
    {
      "title": "Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays",
      "date": "2026-03-18",
      "source": "alpha_vantage",
      "score": -0.477
    },
    {
      "title": "QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline",
      "date": "2026-03-26",
      "source": "alpha_vantage",
      "score": -0.473
    },
    {
      "title": "Isolation of HIS tagged protein from media of CHOK1 cells",
      "date": "2026-03-09",
      "source": "reddit",
      "score": -0.402
    },
    {
      "title": "52 Week Low Stock list below… which ones are you guys buying?!",
      "date": "2026-03-25",
      "source": "reddit",
      "score": -0.338
    },
    {
      "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution",
      "date": "2026-03-26",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt exchange",
      "date": "2026-03-25",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience",
      "date": "2026-03-22",
      "source": "alpha_vantage",
      "score": -0.296
    },
    {
      "title": "Qiagen N.V. Stock (ISIN: NL0012169213) Faces Pressure Amid Life Sciences Slowdown",
      "date": "2026-03-14",
      "source": "alpha_vantage",
      "score": -0.296
    }
  ],
  "raw_data": {
    "total_items": 72,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-27:newsml_PexprN21a:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-27",
        "summary": "QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM (the Netherlands Authority For the Financial Markets). The notification details a transaction on March 23, 2026, where BlackRock, Inc. adjusted its holdings in Qiagen N.V. The distribution overview shows BlackRock's total capital interest at 10.44% and voting rights at 11.59%, held indirectly through various subsidiaries.",
        "sentiment_score": 0.027114,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-27:newsml_Pex1mz4Va:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-27",
        "summary": "This article announces that BlackRock, Inc. has notified the AFM (the Netherlands Authority For the Financial Markets) of a significant change in its holdings and voting rights in QIAGEN N.V. The notification details the distribution of shares and voting rights by various BlackRock entities, categorizing them into real and potential holdings, and specifies the manner of disposal for some shares. Overall, BlackRock's total holding in QIAGEN N.V. is 10.44% and its total voting rights amount to 11.",
        "sentiment_score": 0.003112,
        "sentiment_label": "Neutral",
        "relevance_score": 0.337062,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: Steady Position in Molecular Diagnostics Amid Sector Growth Opportunities",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-steady-position-in-molecular-diagnostics-amid-sector/69007382",
        "date": "2026-03-27",
        "summary": "Qiagen N.V. (QGEN) maintains a stable position in the molecular diagnostics and life sciences sector, providing essential sample and assay technologies for various applications. The company's diversified business model, global footprint, and focus on high-growth areas like next-generation sequencing and human identification make it an attractive consideration for North American investors seeking exposure to the biotech tools space. While facing competition and regulatory risks, Qiagen's consiste",
        "sentiment_score": 0.481025,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen (NYSE:QGEN) Sets New 52-Week Low - Time to Sell?",
        "url": "https://www.marketbeat.com/instant-alerts/qiagen-nyseqgen-sets-new-52-week-low-time-to-sell-2026-03-27/",
        "date": "2026-03-27",
        "summary": "Qiagen (NYSE:QGEN) recently hit a new 52-week low of $38.89, trading below its 50-day and 200-day moving averages, indicating downward pressure. Despite mixed analyst sentiment (five Buys, seven Holds, one Sell) and an average price target of $55.20, the company did beat modest earnings estimates last quarter and has substantial institutional ownership. The article suggests investors consider whether the current low presents a selling opportunity or if the stock has potential for recovery given ",
        "sentiment_score": -0.239402,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/qiagen-n-v-stock-a-core-player-in-molecular-diagnostics-for-long-term/68995799",
        "date": "2026-03-26",
        "summary": "Qiagen N.V. (ISIN: NL0012169213) is highlighted as a leading molecular diagnostics and life sciences tools company, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The article details its business model, core operations emphasizing recurring revenue from consumables, and strong market position in areas like next-generation sequencing and point-of-care testing. It also addresses the company's relevance for North American investors, competitive advantages, a",
        "sentiment_score": 0.840705,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock: A Core Player in Molecular Diagnostics for Long-Term Investor Focus",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-a-core-player-in-molecular-diagnostics-for-long-term/68995799",
        "date": "2026-03-26",
        "summary": "Qiagen N.V. is presented as a key player in molecular diagnostics and life sciences tools, offering sample-to-insight solutions across genomics, diagnostics, and pharma research. The company's business model relies on a \"razor-and-blade\" approach with recurring consumable revenues and a strong global presence. North American investors are encouraged to consider Qiagen due to its significant U.S. revenue exposure, Nasdaq listing, dividend policy, and alignment with ESG factors.",
        "sentiment_score": 0.045721,
        "sentiment_label": "Neutral",
        "relevance_score": 0.319828,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN NV Hits New 52-Week Low at USD 39.26 Amid Ongoing Decline",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/qiagen-nv-hits-new-52-week-low-at-usd-3926-amid-ongoing-decline-3916716",
        "date": "2026-03-26",
        "summary": "QIAGEN NV has reached a new 52-week low of USD 39.26, marking a 13.83% decrease in its stock over the past year. Despite strong financial health indicators like a low debt-to-equity ratio and high operating cash flow, the company has struggled with long-term growth and its stock performance has lagged behind the S&P 500. Its current valuation, however, appears discounted compared to peers.",
        "sentiment_score": -0.42776,
        "sentiment_label": "Bearish",
        "relevance_score": 0.955095,
        "sentiment": {
          "label": "negative",
          "score": -0.473,
          "confidence": 0.47
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent market caution",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-pressure-amid-biotech-sector-volatility-and-recent/68988787",
        "date": "2026-03-26",
        "summary": "Qiagen N.V. stock has fallen 0.54% to EUR 35.33 on the Frankfurt exchange, reflecting broader volatility in the biotech sector. This dip, despite Qiagen's strong position in molecular diagnostics and genomics tools, indicates investor caution due to shifting demand dynamics and macroeconomic headwinds. US investors are advised to monitor this potential entry point, as the company's consumables-driven revenue model offers a degree of stability in an otherwise volatile market.",
        "sentiment_score": -0.217811,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Should You Add QIAGEN Stock to Your Portfolio for Now?",
        "url": "http://www.msn.com/en-us/money/topstocks/should-you-add-qiagen-stock-to-your-portfolio-for-now/ar-AA1GFG7j?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-26",
        "summary": "The article discusses whether QIAGEN (QGEN) stock is a good addition to an investment portfolio. Unfortunately, the provided content is incomplete and lacks the detailed analysis necessary to make an informed decision.",
        "sentiment_score": 0.224627,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces pressure amid biotech sector volatility and recent price dip on Frankfurt exchange",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-pressure-amid-biotech-sector-volatility-and-recent/68987424",
        "date": "2026-03-25",
        "summary": "Qiagen N.V. (NL0012169213) stock recently dipped by 0.54% to EUR 35.33 on the Frankfurt exchange, reflecting broader pressures within the biotech sector. Despite this short-term selling pressure and market volatility, the company maintains a 'Starkes Signal' rating from analysts, suggesting underlying strength and potential for long-term upside. Key business drivers for Qiagen include its strong position in molecular diagnostics, offering recurring revenue from consumables for genomics and infec",
        "sentiment_score": 0.211628,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Should You Add QIAGEN Stock to Your Portfolio for Now?",
        "url": "https://www.msn.com/en-us/money/topstocks/should-you-add-qiagen-stock-to-your-portfolio-for-now/ar-AA1GFG7j?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-25",
        "summary": "NULL",
        "sentiment_score": 0.118272,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "JPMorgan Chase & Co. Has $33.09 Million Stake in Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-has-3309-million-stake-in-qiagen-nv-qgen-2026-03-23/",
        "date": "2026-03-23",
        "summary": "JPMorgan Chase & Co. significantly reduced its stake in Qiagen N.V. by 40.9% in the third quarter, now holding 740,649 shares valued at $33.09 million. Despite JPMorgan's reduction, other institutional investors like Vanguard and Amundi increased their positions, and several new stakes were initiated, leading to approximately 70% institutional ownership of Qiagen. Qiagen recently beat earnings estimates and has a consensus \"Hold\" rating with a target price of $55.20 from analysts.",
        "sentiment_score": 0.147354,
        "sentiment_label": "Neutral",
        "relevance_score": 0.953398,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-pressure-amid-genomics-slowdown-as-dach-investors/68962276",
        "date": "2026-03-22",
        "summary": "Qiagen N.V. shares dipped after mixed Q4 2025 results revealed a 2% revenue decline and slower genomics demand. Despite maintaining its 2026 growth guidance, investors reacted to near-term softness in the genomics segment, though the diagnostics business showed resilience. DACH investors are closely monitoring the stock, given its significance in the European life sciences sector and the potential for recovery through renewed R&D funding and strategic expansions.",
        "sentiment_score": 0.016784,
        "sentiment_label": "Neutral",
        "relevance_score": 0.332639,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Agilent, Danaher could be potential buyers of Qiagen - analyst",
        "url": "https://www.msn.com/en-us/money/companies/agilent-danaher-could-be-potential-buyers-of-qiagen-analyst/ar-AA1UBgHd?ocid=BingNewsVerp",
        "date": "2026-03-22",
        "summary": "This article mentions that an analyst views Agilent and Danaher as potential acquirers for Qiagen. No further details are provided in the current content.",
        "sentiment_score": 0.269595,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "url": "https://www.businesswire.com/news/home/20260320968222/en/Qiagen-Announces-Form-20-F-Annual-Report-Filing-for-2025-Results",
        "date": "2026-03-21",
        "summary": "QIAGEN N.V. announced it has filed its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. Shareholders can access the document on the company's website or request printed copies free of charge. QIAGEN is a global leader in Sample to Insight solutions for Life Sciences and molecular diagnostics.",
        "sentiment_score": 0.019062,
        "sentiment_label": "Neutral",
        "relevance_score": 0.335547,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock rises on strong Q4 earnings and genomics demand surge amid AI biotech push",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-rises-on-strong-q4-earnings-and-genomics-demand-surge/68944548",
        "date": "2026-03-20",
        "summary": "Qiagen N.V. reported stronger-than-expected Q4 results, with revenue beating estimates by 5% and adjusted EPS surpassing forecasts. The growth was driven by demand for genomic tools, particularly in AI-driven drug discovery and diagnostics, leading to a 4.2% intraday rise in its stock on the Frankfurt Stock Exchange. The company provided a positive 2026 guidance, expecting 7-9% revenue growth and increasing its dividend, highlighting its strong position in genomic innovation and relevance for DA",
        "sentiment_score": 0.455412,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "url": "https://www.biospace.com/press-releases/qiagen-announces-form-20-f-annual-report-filing-for-2025-results",
        "date": "2026-03-20",
        "summary": "QIAGEN N.V. has filed its annual report on Form 20-F, including audited consolidated financial statements, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is accessible on QIAGEN's website, and shareholders can request printed copies free of charge. QIAGEN is a global leader in Sample to Insight solutions for life sciences and molecular diagnostics, employing approximately 5,700 people worldwide as of December 31, 2025.",
        "sentiment_score": 0.1178,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "url": "https://sg.finance.yahoo.com/news/qiagen-announces-form-20-f-113000194.html",
        "date": "2026-03-20",
        "summary": "QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the filing of its annual report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. Shareholders can access the document on QIAGEN's website and request printed copies free of charge. QIAGEN is a Netherlands-based global leader in Sample to Insight solutions for Life Sciences and molecular diagnostics.",
        "sentiment_score": 0.14591,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-CMS: QIAGEN N.V.: Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act]",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-20:newsml_PexCr4Fna:0-pta-cms-qiagen-n-v-third-country-release-according-to-article-50-para-1-no-2-of-the-wphg-the-german-securities-trading-act/",
        "date": "2026-03-20",
        "summary": "QIAGEN N.V. has filed its Form 20-F Annual Report for the fiscal year ended December 31, 2025, with the United States Securities and Exchange Commission (SEC). This announcement serves as a third-country release under Article 50 Para. 1, No. 2 of the German Securities Trading Act, ensuring Europe-wide distribution. The report is now accessible on QIAGEN's corporate website.",
        "sentiment_score": 0.011514,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock gains spotlight with new QuantiFERON-TB data amid genomics challenges",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-gains-spotlight-with-new-quantiferon-tb-data-amid/68932335",
        "date": "2026-03-20",
        "summary": "Qiagen N.V. released new clinical data highlighting the efficacy of its QuantiFERON-TB Gold Plus test in reducing tuberculosis progression risk, especially in high-risk groups, counteracting pressure from a slowdown in genomics demand. Despite genomics headwinds impacting stock performance, the company's strong financial health and promising valuation metrics, along with continued innovation in diagnostics, present potential opportunities for investors, particularly in European markets. An upcom",
        "sentiment_score": 0.233234,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. stock faces headwinds from genomics slowdown amid new TB test data",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-faces-headwinds-from-genomics-slowdown-amid-new-tb-test/68923120",
        "date": "2026-03-20",
        "summary": "Qiagen N.V. is experiencing softening demand in its genomics consumables segment despite positive clinical trial data for its QuantiFERON-TB Gold Plus test. The company's razor-and-blade business model is under strain as labs reduce consumable usage, impacting recurring revenue visibility. However, strong performance in bioinformatic subscriptions and the promising TB diagnostic franchise offer a counterbalance, particularly for DACH investors who benefit from local operations and euro-denominat",
        "sentiment_score": 0.096408,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "[IRANNOTICE] QIAGEN N.V. SEC Filing",
        "url": "https://www.stocktitan.net/sec-filings/QGEN/irannotice-qiagen-n-v-sec-filing-e35b8d81babb.html",
        "date": "2026-03-19",
        "summary": "QIAGEN N.V. has filed an IRANNOTICE with the U.S. Securities and Exchange Commission, disclosing information pursuant to the Iran Threat Reduction and Syria Human Rights Act and the Securities Exchange Act. This filing relates to disclosures made in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025. The notice, signed by CFO Roland Sackers, indicates that the company has adhered to these regulations regarding its activities.",
        "sentiment_score": 0.022208,
        "sentiment_label": "Neutral",
        "relevance_score": 0.335408,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
        "url": "https://www.businesswire.com/news/home/20260319519055/en/QIAGEN-Highlights-Newly-Published-Data-Supporting-Efficacy-of-QuantiFERON-for-TB-Prevention",
        "date": "2026-03-19",
        "summary": "QIAGEN announced new clinical and health economic data supporting its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, especially in immunocompromised and high-risk populations. A study showed QFT-Plus reduced the lifetime risk of active TB progression by 41% and lowered healthcare costs compared to tuberculin skin tests in HIV patients. The company will host a World TB Day event on March 24, 2026, to discuss advances in TB detection and prevention, while",
        "sentiment_score": 0.483639,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
        "url": "https://finance.yahoo.com/sectors/healthcare/articles/qiagen-highlights-newly-published-data-200500593.html",
        "date": "2026-03-19",
        "summary": "QIAGEN announced new clinical and health economic data supporting the efficacy of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting TB infection, especially in immunocompromised and other high-risk populations. A recent study found QFT-Plus reduced the modeled lifetime risk of progressing to active TB by 41% compared to tuberculin skin testing, while also lowering healthcare costs. QIAGEN will host a World TB Day event on March 24, 2026, bringing together experts to discuss advanc",
        "sentiment_score": 0.443078,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen’s TB And GI Testing Moves Draw Investor Valuation Interest",
        "url": "https://www.sahmcapital.com/news/content/qiagens-tb-and-gi-testing-moves-draw-investor-valuation-interest-2026-03-20",
        "date": "2026-03-19",
        "summary": "Qiagen (NYSE:QGEN) has released new clinical data supporting its QuantiFERON-TB Gold Plus test for tuberculosis, particularly for high-risk patients, and is planning a global TB awareness event. Additionally, the company received FDA clearance for its QIAstat-Dx Gastrointestinal Panels on the QIAstat-Dx Rise system for use in U.S. clinical laboratories. These developments highlight Qiagen's strategic positioning in infectious disease diagnostics and molecular lab automation, with shares currentl",
        "sentiment_score": 0.500238,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.459,
          "confidence": 0.46
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock (ISIN: NL0012169213) Faces Headwinds Amid Genomics Slowdown and Strategic Shifts",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-isin-nl0012169213-faces-headwinds-amid-genomics/68849383",
        "date": "2026-03-19",
        "summary": "Qiagen N.V. (ISIN: NL0012169213) is experiencing pressure due to a slowdown in demand for genomics consumables, a key revenue driver, as revealed in recent quarterly results. This has led to investor scrutiny over its growth prospects and valuation, particularly for European investors tracking Xetra-traded names. The company's \"razor-and-blade\" business model, while typically strong, is challenged by dipping pull-through rates, though its financial health remains solid amidst a competitive lands",
        "sentiment_score": -0.285516,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays",
        "url": "http://www.msn.com/en-us/money/markets/qiagen-teams-with-gencurix-to-expand-digital-pcr-cancer-assays/ar-AA1HUcEI?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-19",
        "summary": "Qiagen has partnered with South Korean company Gencurix to develop and commercialize digital PCR assays for cancer research and companion diagnostics. This collaboration aims to enhance Qiagen's portfolio in precision medicine for oncology, leveraging Gencurix's expertise in cancer diagnostics. The initial focus will be on the Korean market, with plans for global expansion.",
        "sentiment_score": 0.402894,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays",
        "url": "https://www.msn.com/en-us/money/markets/qiagen-teams-with-gencurix-to-expand-digital-pcr-cancer-assays/ar-AA1HUcEI?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-18",
        "summary": "Qiagen has partnered with South Korean molecular diagnostics firm Gencurix to develop and commercialize digital PCR assays for cancer research and treatment. The collaboration will initially focus on developing tests for new cancer biomarkers based on Gencurix's clinically validated oncology markers, which are used in its LiquidARRAY platform. This partnership aims to expand the range of available digital PCR solutions for oncology applications.",
        "sentiment_score": 0.427,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-18:newsml_Pex9QsnSa:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-18",
        "summary": "QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM on March 17, 2026. BlackRock, Inc. is identified as the person obliged to notify, with details provided on their direct and indirect holdings of QIAGEN N.V. shares and voting rights, totaling a capital interest of 10.33% and voting rights of 11.47%.",
        "sentiment_score": 0.004316,
        "sentiment_label": "Neutral",
        "relevance_score": 0.340927,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Moors & Cabot Inc. Acquires 154,851 Shares of Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-moors-cabot-inc-acquires-154851-shares-of-qiagen-nv-qgen-2026-03-17/",
        "date": "2026-03-17",
        "summary": "Moors & Cabot Inc. significantly increased its stake in Qiagen N.V. (NYSE:QGEN) by 78.2% in the third quarter, acquiring an additional 154,851 shares. This purchase brings their total holding to 352,809 shares, valued at approximately $15.76 million, making Qiagen their 29th largest position. Other major institutional investors also expanded their holdings, with institutional ownership now accounting for about 70% of Qiagen.",
        "sentiment_score": 0.268027,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.978343,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. Stock (ISIN: NL0012169213) Faces Pressure Amid Life Sciences Slowdown",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/qiagen-n-v-stock-isin-nl0012169213-faces-pressure-amid-life-sciences/68680467",
        "date": "2026-03-14",
        "summary": "Qiagen N.V. (NL0012169213) is experiencing pressure due to mixed quarterly results and cautious guidance in the diagnostics sector, particularly amidst a slowdown in life sciences R&D spending. While its core consumables business remains strong, the genomics segment faces headwinds from delayed research funding. European investors are closely monitoring the company's resilience, strategic diversification, and potential for recovery in precision medicine as management reaffirms full-year guidance",
        "sentiment_score": 0.011886,
        "sentiment_label": "Neutral",
        "relevance_score": 0.319598,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Wellington Management Group LLP Lowers Stake in Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-lowers-stake-in-qiagen-nv-qgen-2026-03-14/",
        "date": "2026-03-14",
        "summary": "Wellington Management Group LLP has reduced its stake in Qiagen N.V. ($QGEN) by 10.4% in the third quarter, selling over 2.6 million shares but still holding a significant portion of the company valued at over $1 billion. Despite the stock trading near its 12-month low, Qiagen recently exceeded EPS and revenue estimates. Analyst opinions are mixed, with a consensus \"Hold\" rating and an average price target of $55.20, although some firms have issued \"Overweight\" ratings.",
        "sentiment_score": 0.03103,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Deutsche Bank upgrades Qiagen NV (QGEN)",
        "url": "https://www.msn.com/en-us/money/top-stocks/deutsche-bank-upgrades-qiagen-nv-qgen/ar-AA1YAAPE",
        "date": "2026-03-14",
        "summary": "Deutsche Bank has upgraded its rating for Qiagen NV (QGEN). This indicates a more positive outlook from the bank regarding the company's stock performance.",
        "sentiment_score": 0.437005,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen N.V. $QGEN Position Raised by Perbak Capital Partners LLP",
        "url": "https://www.marketbeat.com/instant-alerts/filing-qiagen-nv-qgen-position-raised-by-perbak-capital-partners-llp-2026-03-14/",
        "date": "2026-03-14",
        "summary": "Perbak Capital Partners LLP significantly increased its stake in Qiagen N.V. (NYSE:QGEN) by 78.2% in the third quarter, making the stock its 13th-largest holding. Qiagen recently beat quarterly earnings and revenue estimates, showing a 3.6% year-over-year revenue increase. Despite a consensus \"Hold\" rating from analysts, some firms have issued \"Buy\" ratings with target prices ranging from $54.00 to $59.00.",
        "sentiment_score": 0.28817,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Dnca Finance Acquires 39,063 Shares of Qiagen N.V. $QGEN",
        "url": "https://www.marketbeat.com/instant-alerts/filing-dnca-finance-acquires-39063-shares-of-qiagen-nv-qgen-2026-03-14/",
        "date": "2026-03-14",
        "summary": "Dnca Finance increased its stake in Qiagen N.V. (NYSE:QGEN) by 7.5% in the third quarter, purchasing an additional 39,063 shares to own a total of 558,481 shares. Other institutional investors also adjusted their positions in Qiagen, with Johnson Investment Counsel Inc., Bessemer Group Inc., and Covestor Ltd among those increasing their holdings. Qiagen currently has a consensus \"Hold\" rating from analysts with an average target price of $55.20, and the company recently reported Q3 earnings that",
        "sentiment_score": 0.148453,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BlackRock Reports 10.6% Capital and 11.8% Voting Stake in Qiagen",
        "url": "https://www.tipranks.com/news/company-announcements/blackrock-reports-10-6-capital-and-11-8-voting-stake-in-qiagen",
        "date": "2026-03-13",
        "summary": "BlackRock, Inc. and its affiliates have disclosed a substantial holding in Qiagen (QGEN) as of March 10, 2026, comprising 10.61% of the company's capital and 11.76% of its voting rights. These indirect holdings, reported after notification from the Dutch financial regulator AFM, include a mix of ordinary shares and contracts for difference. This disclosure highlights BlackRock's significant influence on Qiagen's shareholder structure and governance.",
        "sentiment_score": 0.024,
        "sentiment_label": "Neutral",
        "relevance_score": 0.337699,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Deutsche Bank upgrades Qiagen stock rating to buy on valuation",
        "url": "https://www.investing.com/news/analyst-ratings/deutsche-bank-upgrades-qiagen-stock-rating-to-buy-on-valuation-93CH-4559219",
        "date": "2026-03-13",
        "summary": "Deutsche Bank has upgraded its rating for Qiagen (NYSE:QGEN) stock from Hold to Buy, maintaining a $54.00 price target. The upgrade follows a nearly 30% drop in Qiagen's shares since merger and acquisition speculation in late January, which has effectively removed any takeover premium from its valuation. The firm highlights Qiagen's undemanding valuation, robust balance sheet, and projected average annual shareholder returns of approximately 13%, driven by earnings growth, dividends, and share r",
        "sentiment_score": 0.417883,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-13:newsml_PextNQMVa:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-13",
        "summary": "This article provides a release from QIAGEN N.V. regarding a voting rights announcement made by the AFM (the Netherlands Authority For the Financial Markets). The notification, related to BlackRock, Inc., details various transactions involving QIAGEN N.V. shares and voting rights, including direct and indirect holdings, as well as capital interest and voting rights percentages.",
        "sentiment_score": 0.00173,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-13:newsml_PexhMdN2a:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-13",
        "summary": "QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the AFM on March 12, 2026. The announcement details BlackRock, Inc.'s holdings in QIAGEN N.V. shares as of March 9, 2026, including various types of shares, voting rights, and capital interests, distributed across several BlackRock entities. BlackRock, Inc. holds a total capital interest of 10.29% and total voting rights of 11.43% in QIAGEN N.V.",
        "sentiment_score": 0.005895,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Deutsche Bank Upgrades Qiagen NV(QGEN.US) to Buy Rating",
        "url": "https://news.futunn.com/en/post/70045520/deutsche-bank-upgrades-qiagen-nv-qgenus-to-buy-rating",
        "date": "2026-03-13",
        "summary": "Deutsche Bank analyst Jan Koch has upgraded Qiagen NV (QGEN.US) to a buy rating. According to TipRanks data, Koch has a 25.5% success rate and a -15.4% average return over the past year. This information is intended for educational purposes and is not investment advice.",
        "sentiment_score": 0.540994,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Today's Analyst Upgrade: Deutsche Bank Recommends Buy for QGEN | QGEN Stock News",
        "url": "https://www.gurufocus.com/news/8706321/todays-analyst-upgrade-deutsche-bank-recommends-buy-for-qgen-qgen-stock-news",
        "date": "2026-03-13",
        "summary": "Deutsche Bank has upgraded its rating for Qiagen (QGEN) from Hold to Buy, maintaining a price target of $54.00 USD. This upgrade follows several recent analyst adjustments and is expected to boost investor confidence in the company. Qiagen, which specializes in proprietary sample and assay technology, is also projected to have an average target price of $54.25 by 14 analysts, implying a 31.93% upside from its current price.",
        "sentiment_score": 0.428104,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.426,
          "confidence": 0.43
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Deutsche Bank upgrades Qiagen stock rating to buy on valuation",
        "url": "https://m.investing.com/news/analyst-ratings/deutsche-bank-upgrades-qiagen-stock-rating-to-buy-on-valuation-93CH-4559219?ampMode=1",
        "date": "2026-03-13",
        "summary": "Deutsche Bank upgraded Qiagen NV (NYSE:QGEN) from Hold to Buy, maintaining a price target of $54.00, citing valuation after a significant stock decline. The firm expects investor focus to return to operational performance and projects average annual shareholder returns of approximately 13%, driven by earnings, dividends, and share repurchases. This upgrade comes amidst discussions about Qiagen's strategic options and new board appointments.",
        "sentiment_score": 0.40024,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Deutsche Bank Upgrades Qiagen NV (QGEN) to Buy",
        "url": "https://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Upgrades+Qiagen+NV+%28QGEN%29+to+Buy/26155566.html",
        "date": "2026-03-13",
        "summary": "Deutsche Bank has upgraded its rating for Qiagen NV (QGEN) from Hold to Buy, setting a price target of $54.00. This article, however, is a premium offering and requires a subscription to access the full details of the analyst's report.",
        "sentiment_score": 0.435922,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-11:newsml_Pex2ZLc1a:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-12",
        "summary": "This article provides a release from QIAGEN N.V. regarding a voting rights announcement issued by the AFM (the Netherlands Authority For the Financial Markets). The notification, dated March 9, 2026, details changes in voting rights related to Bank of America Corporation's holdings in QIAGEN N.V., including both real and potential interests across various share types and financial instruments. The announcement includes a detailed breakdown of shares, voting rights, and capital interest, as well ",
        "sentiment_score": 0.043794,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Qiagen discloses Bank of America’s 3.05% stake following AFM notification",
        "url": "https://www.tipranks.com/news/company-announcements/qiagen-discloses-bank-of-americas-3-05-stake-following-afm-notification",
        "date": "2026-03-11",
        "summary": "Qiagen announced that Bank of America holds a 3.05% interest in the company through ordinary shares, swaps, and options, as reported by the Netherlands Authority for the Financial Markets (AFM). This disclosure provides transparency regarding Bank of America's notable institutional investment in Qiagen, potentially influencing trading dynamics and governance. Qiagen trades under ISIN NL0015002SN0, with a current market cap of $8.89 billion.",
        "sentiment_score": 0.010052,
        "sentiment_label": "Neutral",
        "relevance_score": 0.30451,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "BlackRock Builds Significant Stake in Qiagen with Over 11% of Voting Rights",
        "url": "https://www.tipranks.com/news/company-announcements/blackrock-builds-significant-stake-in-qiagen-with-over-11-of-voting-rights",
        "date": "2026-03-11",
        "summary": "BlackRock and its affiliates have acquired a significant stake in Qiagen, holding 10.52% of its share capital and 11.66% of voting rights. This substantial investment by one of the world's largest asset managers highlights persistent institutional interest in Qiagen, a company specializing in life sciences and diagnostics. A recent analyst rating on QGEN stock is a Buy with a $51.00 price target.",
        "sentiment_score": 0.392474,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-11:newsml_Pex5bvMga:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-11",
        "summary": "QIAGEN N.V. (QIA) has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the Netherlands Authority For the Financial Markets (AFM). The notification, dated March 10, 2026, details that BlackRock, Inc. has disclosed its holdings in QIAGEN N.V., including various types of shares and associated voting rights, both real and potential, held indirectly through several BlackRock entities. The total capital interest held by BlackRock is stated as 1",
        "sentiment_score": 0.028438,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Release according to Article 40, Section 1 of the WpHG",
        "url": "https://www.tradingview.com/news/reuters.com,2026-03-11:newsml_PexhCH4ra:0-release-according-to-article-40-section-1-of-the-wphg/",
        "date": "2026-03-11",
        "summary": "QIAGEN N.V. has released an announcement regarding voting rights according to Article 40, Section 1 of the WpHG. This notification, disclosed by the AFM, details BlackRock, Inc.'s holdings in QIAGEN N.V., providing a breakdown of direct and indirect real and potential capital interests and voting rights, as of a transaction date of March 6, 2026. The report includes granular data on the types of shares and voting rights held across various BlackRock entities.",
        "sentiment_score": 0.047466,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Why is Qiagen (QGEN) down 9.4% since last earnings report?",
        "url": "https://www.msn.com/en-us/money/topstocks/why-is-qiagen-qgen-down-94-since-last-earnings-report/ar-AA1XFPlk",
        "date": "2026-03-11",
        "summary": "This article analyzes financial factors related to Qiagen's stock performance following its latest earnings report. It focuses on several key metrics including earnings per share, revenue, and analyst expectations. The content appears to be a stub, as no detailed analysis or financial data is provided beyond the title.",
        "sentiment_score": -0.415703,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System",
        "url": "https://www.businesswire.com/news/home/20260310647622/en/QIAGEN-Receives-U.S.-Clearance-for-Gastrointestinal-Panels-on-Fully-Automated-QIAstat-Dx-Rise-Syndromic-Testing-System",
        "date": "2026-03-11",
        "summary": "QIAGEN announced U.S. FDA clearance for its QIAstat-Dx Gastrointestinal Panels on the fully automated QIAstat-Dx Rise syndromic testing system. This clearance allows laboratories to run both respiratory and GI panels on a single high-throughput system, enhancing testing capacity and automation for detecting multiple pathogens. The system provides rapid results in about one hour with minimal hands-on time, supporting timely clinical decisions for gastrointestinal and respiratory infections.",
        "sentiment_score": 0.426844,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "reddit",
        "subreddit": "EverHint",
        "title": "EverHint – EMA10 × EMA30 Crossover – Top 10 Buy and Top 10 Sell Signals for Mar 25, 2026",
        "text": "## What This Signal Is (Quick)\n\nThis strategy detects **fresh crossovers** between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30):\n\n  * **Buy Signal (EMA10_x_EMA30_Buy)** : EMA(10) crosses **above** EMA(30) on today's close\n\n    * Short-term momentum overtakes medium-term trend\n    * Suggests acceleration in upward price movement\n    * Ideal for swing trading (1-4 week holding periods)\n  * **Sell Signal (EMA10_x_EMA30_Sell)** : EMA(10) crosses **b",
        "author": "Mamuthone125",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-26",
        "url": "https://reddit.com/r/EverHint/comments/1s3xb55/everhint_ema10_ema30_crossover_top_10_buy_and_top/",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "reddit",
        "subreddit": "EverHint",
        "title": "EverHint Lens - Hims & Hers Health, Inc. (HIMS) - Yahoo Top Gainer (+40%) Stock Analysis - March 09, 2026",
        "text": "**Analysis Date** : 2026-03-09  \n**Sector** : Healthcare  \n**Industry** : Medical - Equipment & Services  \n**Exchange** : NYSE\n\n## Executive Summary\n\nHims & Hers Health, Inc. is currently trading at **$22.12** (🟢 +40.52% today) with a market capitalization of **$4.86B**.\n\nHims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase",
        "author": "Mamuthone125",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-09",
        "url": "https://reddit.com/r/EverHint/comments/1rp5lp9/everhint_lens_hims_hers_health_inc_hims_yahoo_top/",
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "QIAGEN Buffers question",
        "text": "We do quite a few Plasmid MAXI preps using The QIAGEN Endo-Free MAXI Kit. But pretty much every buffer can be purchased separately except the Endo-Tested Buffer QC (non Endo-Tested can be purchased) and the Endo-Tested Buffer QN. I know that I can also make these myself, but not Endo-Tested. Anyone make these themselves and what do you use to Endo-Test (more make sure it is Endotoxin free)? These 2 buffers are a huge Stop Gap. We have oodles of every buffer but always have to buy a new kit to ge",
        "author": "SnooPredictions138",
        "score": 3,
        "num_comments": 10,
        "date": "2026-03-09",
        "url": "https://reddit.com/r/labrats/comments/1rp5t8p/qiagen_buffers_question/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "Combining CTAB Extraction with Qiagen DNeasy kit",
        "text": "Hi guys, I am looking to extract DNA for Japanese knotweed leaves, and after performing an extraction with the Qiagen DNEasy kit it did not yield any DNA. Since I performed the lysis with -20 frozen leaves, I suspect that might be the cause. The thing is that I do not have liquid nitrogen or a -80 at my disposal since our lab is extremely basic and not tailored towards DNA work at all, and also no fume hood so a safe extraction with chloroform is not possible. What are my options here? What I do",
        "author": "GerritDeSenieleEend",
        "score": 1,
        "num_comments": 5,
        "date": "2026-03-04",
        "url": "https://reddit.com/r/labrats/comments/1rki01q/combining_ctab_extraction_with_qiagen_dneasy_kit/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-20",
        "url": "https://reddit.com/r/Quantisnow/comments/1rytsfd/qiagen_announces_form_20f_annual_report_filing/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "StockTitan",
        "title": "QGEN | Qiagen Announces Form 20-F Annual Report Filing for 2025 Results",
        "text": "",
        "author": "Stock_Titan",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-20",
        "url": "https://reddit.com/r/StockTitan/comments/1rytqc0/qgen_qiagen_announces_form_20f_annual_report/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-19",
        "url": "https://reddit.com/r/Quantisnow/comments/1ryavgw/qiagen_highlights_newly_published_data_supporting/",
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "Qiagen upgraded by Deutsche Bank with a new price target",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-13",
        "url": "https://reddit.com/r/Quantisnow/comments/1rsmci3/qiagen_upgraded_by_deutsche_bank_with_a_new_price/",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "reddit",
        "subreddit": "Quantisnow",
        "title": "QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System",
        "text": "",
        "author": "Quantisnow",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-10",
        "url": "https://reddit.com/r/Quantisnow/comments/1rq9jk0/qiagen_receives_us_clearance_for_gastrointestinal/",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "reddit",
        "subreddit": "StockTitan",
        "title": "QGEN | QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System",
        "text": "",
        "author": "Stock_Titan",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-10",
        "url": "https://reddit.com/r/StockTitan/comments/1rq9ggi/qgen_qiagen_receives_us_clearance_for/",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "reddit",
        "subreddit": "TheRaceTo10Million",
        "title": "52 Week Low Stock list below… which ones are you guys buying?!",
        "text": "All these stocks hit new 52 WEEK LOWS at some point today\n\nMercadolibre $MELI\n\nAdobe $ADBE\n\nSnapchat $SNAP\n\nAbbott $ABT\n\nBroadridge $BR\n\nChewy $CHWY\n\nCostar $CSGP\n\nCintas $CTAS\n\nDropbox $DBX\n\nDiageo $DEO\n\nDomino's Pizza $DPZ\n\nFair Isaac $FICO\n\nGen Digital $GEN\n\nKraft Heinz $KHC\n\nMobileye $MBLY\n\nMccormick $MKC\n\n$OTIS\n\nQiagen $QGEN\n\n$SAP\n\nSBA Comm $SBAC\n\nStryker $SYK\n\nMolson Coors $TAP\n\nTransdigm $TDG\n\nAtlassian $TEAM\n\nTencent Music $TME\n\nTractor Supply $TSCO\n\nUnilever $UL\n\nWingstop $WING\n\nZoetis ",
        "author": "ETFSimulator",
        "score": 65,
        "num_comments": 57,
        "date": "2026-03-25",
        "url": "https://reddit.com/r/TheRaceTo10Million/comments/1s37vmj/52_week_low_stock_list_below_which_ones_are_you/",
        "sentiment": {
          "label": "negative",
          "score": -0.338,
          "confidence": 0.34
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "What's contaminating my DNA?",
        "text": "I need help, fellow labrats. I'm desperate. I've tried everything to clean up this DNA and it's not working. I made a throwaway account for this post because I'm too embarrassed to ask on main.\n\nSOMETHING is contaminating my DNA samples and no matter what I do, the contamination remains.\n\nI am extracting DNA from environmental samples - soil and plant roots. I need high molecular weight DNA for nanopore sequencing. But my DNA is bad. The DNA pellet itself is a mid-brown colour (cappuccino-ish). ",
        "author": "phenolfailure",
        "score": 7,
        "num_comments": 32,
        "date": "2026-03-16",
        "url": "https://reddit.com/r/labrats/comments/1rv7u4c/whats_contaminating_my_dna/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "Opinionns on DigitalPCR",
        "text": "Hello fellow scientists !\n\nOur lab have recently been looking into digitalPCR, and like to hear about your experiences with the systems and the post sales experience.\n\nFor now we are inclined toward Thermo Fischer and Qiagen, with the plate type platform.\n\nLooked into the BIORAD system, 4 steps and 4 equipments beyond the qPCR standard workflow looked a bit harsh.\n\nThanks in advance !",
        "author": "IllustriousTax3916",
        "score": 12,
        "num_comments": 24,
        "date": "2026-03-13",
        "url": "https://reddit.com/r/labrats/comments/1rsvnbl/opinionns_on_digitalpcr/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "Sanger Sequencing Problem!!",
        "text": "I have read almost all of the sanger Sequencing issues on reddit but my case seems to be a bit different, therefore posting.\n\nI am performing a study on Human genomic DNA. I have a primer with product size 912 bp (another with 812 bp) and my missense variant lies almost at the centre of this product size. I perform PCR, followed by a gel, then a PCR product purification step, followed by another gel (to make sure I loose no product during PPP), then Sequencing PCR, followed by the last product p",
        "author": "FreeloaderFatso",
        "score": 1,
        "num_comments": 15,
        "date": "2026-03-06",
        "url": "https://reddit.com/r/labrats/comments/1rmg5x3/sanger_sequencing_problem/",
        "sentiment": {
          "label": "negative",
          "score": -0.508,
          "confidence": 0.51
        }
      },
      {
        "source": "reddit",
        "subreddit": "Microbiome",
        "title": "Seeking Advice/Guidance - Mice Feces for 16s rRNA sequencing",
        "text": "Hello everyone.\n\nTo preface: I have just graduated from undergrad, and I am new to a relatively new biomedical engineering lab that has never done any microbial work. I have never done 16s rRNA seq. We aim to characterize the mouse microbiome from fecal samples.\n\nDoes anyone have a protocol or some useful links that they can share to help get me on track? I have read a lot of papers, but every protocol varies, as some send it off to a sequencing facility, some do it in-house.\n\nCurrently, I under",
        "author": "No_Understanding7354",
        "score": 3,
        "num_comments": 8,
        "date": "2026-03-24",
        "url": "https://reddit.com/r/Microbiome/comments/1s24p1f/seeking_adviceguidance_mice_feces_for_16s_rrna/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "Seeking Advice/Guidance - Mice Feces for 16s rRNA sequencing",
        "text": "Hello everyone.\n\nTo preface: I have just graduated from undergrad, and I am new to a relatively new biomedical engineering lab that has never done any microbial work. I have never done 16s rRNA seq. We are looking to characterize the microbiome of mice from their feces.\n\n  \nDoes anyone have a protocol or some useful links that they can share to help get me on track? I have read a lot of papers, but every protocol varies, as some send it off to a sequencing facility, some do it in-house. \n\n  \nCur",
        "author": "No_Understanding7354",
        "score": 2,
        "num_comments": 6,
        "date": "2026-03-24",
        "url": "https://reddit.com/r/labrats/comments/1s24l4e/seeking_adviceguidance_mice_feces_for_16s_rrna/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "Daytrading",
        "title": "52 Week Low value.. which ones are you buying and why?",
        "text": "All these stocks hit new 52 WEEK LOWS at some point today\n\nMercadolibre $MELI\n\nAdobe $ADBE\n\nSnapchat $SNAP\n\nAbbott $ABT\n\nBroadridge $BR\n\nChewy $CHWY\n\nCostar $CSGP\n\nCintas $CTAS\n\nDropbox $DBX\n\nDiageo $DEO\n\nDomino's Pizza $DPZ\n\nFair Isaac $FICO\n\nGen Digital $GEN\n\nKraft Heinz $KHC\n\nMobileye $MBLY\n\nMccormick $MKC\n\n$OTIS\n\nQiagen $QGEN\n\n$SAP\n\nSBA Comm $SBAC\n\nStryker $SYK\n\nMolson Coors $TAP\n\nTransdigm $TDG\n\nAtlassian $TEAM\n\nTencent Music $TME\n\nTractor Supply $TSCO\n\nUnilever $UL\n\nWingstop $WING\n\nZoetis ",
        "author": "ETFSimulator",
        "score": 0,
        "num_comments": 2,
        "date": "2026-03-25",
        "url": "https://reddit.com/r/Daytrading/comments/1s37wdp/52_week_low_value_which_ones_are_you_buying_and/",
        "sentiment": {
          "label": "positive",
          "score": 0.077,
          "confidence": 0.08
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "Aquatic Plant DNA Isolation Help!",
        "text": "Does anyone have experience using either the Qiagen DNeasy Plant Mini or Pro kits to extract DNA from aquatic plant species? I’m having a hell of a time trying to dial in ideal amount of starting tissue, disruption strength/duration, and lysis conditions. So far I’ve been unable to get more than 1ng/ul consistently and the gels often show smearing below the HMW band. Any tips would be greatly appreciated.",
        "author": "Solar-Crayfish",
        "score": 1,
        "num_comments": 3,
        "date": "2026-03-06",
        "url": "https://reddit.com/r/labrats/comments/1rmfjee/aquatic_plant_dna_isolation_help/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "wallstreetbetsGER",
        "title": "Rückblick - Gewinner -- Verlierer --- KW 11",
        "text": "",
        "author": "Superb-Neck-5160",
        "score": 8,
        "num_comments": 0,
        "date": "2026-03-15",
        "url": "https://reddit.com/r/wallstreetbetsGER/comments/1rue0hh/rückblick_gewinner_verlierer_kw_11/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "labrats",
        "title": "Isolation of HIS tagged protein from media of CHOK1 cells",
        "text": "I have expressed some proteins with a His tag in CHOK1 cells. The protein should be secreted in the media (I used F12 nutrient mix+10%FBS+P/S). I was thinking to use QIAGENs Ni-NTA spin column for isolation, but I am confused as the kit is primarily for E. coli cell lysates, and I am concerned the media will also affect the binding to the column. Has anyone done something similar? Any tips? ",
        "author": "BasisTop9704",
        "score": 1,
        "num_comments": 1,
        "date": "2026-03-09",
        "url": "https://reddit.com/r/labrats/comments/1rpdsiy/isolation_of_his_tagged_protein_from_media_of/",
        "sentiment": {
          "label": "negative",
          "score": -0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "reddit",
        "subreddit": "asktraders",
        "title": "📈📉 Analyst Upgrades & Downgrades — Mar 13 (Fri)",
        "text": "\n🔻 **Downgrades**\n- **TIC** — TIC Solutions → JP Morgan  \n- **ABX** — Abacus Global Management → Piper Sandler  \n- **NRDS** — Nerdwallet → Morgan Stanley  \n- **KLC** — KinderCare Learning → Morgan Stanley & Baird  \n- **EVCM** — EverCommerce → Citizens  \n\n🔺 **Upgrades**\n- **KNX** — Knight-Swift → Citigroup  \n- **LIN** — Linde → JP Morgan  \n- **AA** — Alcoa → JP Morgan  \n- **NTR** — Nutrien → Wells Fargo  \n- **APD** — Air Products → Wells Fargo  \n- **CE** — Celanese → Wells Fargo  \n- **OLLI** — Ol",
        "author": "Asktraders_com",
        "score": 1,
        "num_comments": 0,
        "date": "2026-03-13",
        "url": "https://reddit.com/r/asktraders/comments/1rsn60c/analyst_upgrades_downgrades_mar_13_fri/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "reddit",
        "subreddit": "WallStreetbetsELITE",
        "title": "Why traders watch microcap biotech before major study updates",
        "text": "One thing experienced biotech traders look for is a small company approaching major clinical data milestones.\n\nRight now there is a diagnostics company trading under $1 that is running a 2k patient US study for colorectal cancer screening technology. That scale is significant for a company with a small market cap because clinical validation can dramatically increase visibility if results remain strong.\n\nThe technology combines DNA biomarkers, mRNA biomarkers, and AI analysis to improve detection",
        "author": "NoahReed14",
        "score": 2,
        "num_comments": 0,
        "date": "2026-03-06",
        "url": "https://reddit.com/r/WallStreetbetsELITE/comments/1rmfby3/why_traders_watch_microcap_biotech_before_major/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}